Icecure Medical Stock Earnings Reports

IceCure reported a strong start to 2026 with Q1 revenue up 26% year‑over‑year, driven by an 84% increase in North America and 31% growth in the U.S., reflecting both new ProSense system placements and higher disposable probe utilization. The company has accelerated U.S. commercial momentum following FDA clearance for low‑risk early breast cancer: active U.S. accounts rose from 13 to 19 (a 46% increase), and management expects continued growth in active accounts in Q2. Demand has been amplified by recent medical conferences, updated clinical guidelines, growing investigator‑led research, and expanding reimbursement pathways (existing facility CPT code ~ $4k; CPT‑1 submission planned in June with potential physician reimbursement by 2028; possible transitional pass‑through payment of ~$9k by early 2027). IceCure is launching the Choice post‑market study (FDA approved) across 30 hybrid clinical/commercial U.S. sites to accelerate adoption and generate additional real‑world data. International interest has also increased post‑FDA clearance (Europe, Asia, Americas). Management is expanding the U.S. commercial team to support expected sustained conversion of leads into system sales and installations throughout 2026 and into 2027.